Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study

Figure 3

June 30, 2019, follow-up of 190 patients who were maintained on sacubitril/valsartan for at least six months (up to four years), indicating that 164 were still alive, 23 had died, and three did not attend the follow-up appointment.